221 related articles for article (PubMed ID: 16734516)
1. Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer's disease.
Lukiw WJ
Expert Rev Neurother; 2006 May; 6(5):683-93. PubMed ID: 16734516
[TBL] [Abstract][Full Text] [Related]
2. 24S-hydroxycholesterol: a marker of brain cholesterol metabolism.
Lütjohann D; von Bergmann K
Pharmacopsychiatry; 2003 Sep; 36 Suppl 2():S102-6. PubMed ID: 14574622
[TBL] [Abstract][Full Text] [Related]
3. The role of 24S-hydroxycholesterol in Alzheimer's disease.
Kölsch H; Lütjohann D; von Bergmann K; Heun R
J Nutr Health Aging; 2003; 7(1):37-41. PubMed ID: 12679839
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease.
Reiss AB; Siller KA; Rahman MM; Chan ES; Ghiso J; de Leon MJ
Neurobiol Aging; 2004 Sep; 25(8):977-89. PubMed ID: 15212822
[TBL] [Abstract][Full Text] [Related]
5. Brain-membrane cholesterol in Alzheimer's disease.
Eckert GP; Kirsch C; Müller WE
J Nutr Health Aging; 2003; 7(1):18-23. PubMed ID: 12679836
[TBL] [Abstract][Full Text] [Related]
6. Alterations in cholesterol metabolism as a risk factor for developing Alzheimer's disease: Potential novel targets for treatment.
Loera-Valencia R; Goikolea J; Parrado-Fernandez C; Merino-Serrais P; Maioli S
J Steroid Biochem Mol Biol; 2019 Jun; 190():104-114. PubMed ID: 30878503
[TBL] [Abstract][Full Text] [Related]
7. PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease.
Holzapfel J; Heun R; Lütjohann D; Jessen F; Maier W; Kölsch H
Neurosci Lett; 2006 Nov; 408(1):57-61. PubMed ID: 16979821
[TBL] [Abstract][Full Text] [Related]
8. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.
Vega GL; Weiner MF; Lipton AM; Von Bergmann K; Lutjohann D; Moore C; Svetlik D
Arch Neurol; 2003 Apr; 60(4):510-5. PubMed ID: 12707064
[TBL] [Abstract][Full Text] [Related]
9. Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease.
Popp J; Meichsner S; Kölsch H; Lewczuk P; Maier W; Kornhuber J; Jessen F; Lütjohann D
Biochem Pharmacol; 2013 Jul; 86(1):37-42. PubMed ID: 23291240
[TBL] [Abstract][Full Text] [Related]
10. Oxysterols and Alzheimer's disease.
Björkhem I; Heverin M; Leoni V; Meaney S; Diczfalusy U
Acta Neurol Scand Suppl; 2006; 185():43-9. PubMed ID: 16866910
[TBL] [Abstract][Full Text] [Related]
11. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration.
Pac-Soo C; Lloyd DG; Vizcaychipi MP; Ma D
J Alzheimers Dis; 2011; 27(1):1-10. PubMed ID: 21734347
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease.
Popp J; Lewczuk P; Kölsch H; Meichsner S; Maier W; Kornhuber J; Jessen F; Lütjohann D
J Neurochem; 2012 Oct; 123(2):310-6. PubMed ID: 22845771
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of 24S-hydroxycholesterol in neuronal SK-N-BE cells treated with hexacosanoic acid (C26:0): argument in favor of 24S-hydroxycholesterol as a potential biomarker of neurolipotoxicity.
Zarrouk A; Hammami M; Moreau T; Lizard G
Rev Neurol (Paris); 2015 Feb; 171(2):125-9. PubMed ID: 25577946
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of statins in Alzheimer's disease.
Kandiah N; Feldman HH
J Neurol Sci; 2009 Aug; 283(1-2):230-4. PubMed ID: 19321181
[TBL] [Abstract][Full Text] [Related]
15. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders.
Shafaati M; Solomon A; Kivipelto M; Björkhem I; Leoni V
Neurosci Lett; 2007 Sep; 425(2):78-82. PubMed ID: 17822846
[TBL] [Abstract][Full Text] [Related]
16. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma.
Burgess BL; McIsaac SA; Naus KE; Chan JY; Tansley GH; Yang J; Miao F; Ross CJ; van Eck M; Hayden MR; van Nostrand W; St George-Hyslop P; Westaway D; Wellington CL
Neurobiol Dis; 2006 Oct; 24(1):114-27. PubMed ID: 16899370
[TBL] [Abstract][Full Text] [Related]
17. Circulating biomarkers of cognitive decline and dementia.
Solfrizzi V; D'Introno A; Colacicco AM; Capurso C; Todarello O; Pellicani V; Capurso SA; Pietrarossa G; Santamato V; Capurso A; Panza F
Clin Chim Acta; 2006 Feb; 364(1-2):91-112. PubMed ID: 16139826
[TBL] [Abstract][Full Text] [Related]
18. Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease.
Hook V; Kindy M; Hook G
Biol Chem; 2007 Feb; 388(2):247-52. PubMed ID: 17261088
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol-modifying strategies for Alzheimer's disease.
Solomon A; Kivipelto M
Expert Rev Neurother; 2009 May; 9(5):695-709. PubMed ID: 19402779
[TBL] [Abstract][Full Text] [Related]
20. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
